Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inge M W Verberk

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Journal of Alzheimer'S Disease : JAD|February 2, 2024
The Association of Alzheimer's Disease-Related Blood-Based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in KinshasaMegan Schwinne, Alvaro Alonso, Blaine R Roberts, et al.
Alzheimer'S Research & Therapy|December 20, 2024
Analytical and clinical performance of eight Simoa<sup>®</sup> and Lumipulse<sup>®</sup> assays for automated measurement of plasma p-tau181 and p-tau217Anna L Wojdała, Jeroen Vanbrabant, Sherif Bayoumy, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 7, 2024
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohortsGiovanni Bellomo, Sherif Bayoumy, Alfredo Megaro, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 21, 2021
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tauShorena Janelidze, Sebastian Palmqvist, Antoine Leuzy, et al.
Alzheimer'S Research & Therapy|December 5, 2021
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231Sherif Bayoumy, Inge M W Verberk, Ben den Dulk, et al.
Alzheimer'S Research & Therapy|July 1, 2026
The potential of key Alzheimer's plasma biomarkers to mimic tau PET MUBADA-based disease stagingInge M W Verberk, Lotte A de Koning, Emma M Coomans, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 13, 2023
Association of plasma biomarkers with cognitive function in persons with dementia and cognitively healthy in the Democratic Republic of CongoJean Ikanga, Saranya Sundaram Patel, Blaine R Roberts, et al.
Translational Psychiatry|January 12, 2021
Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's diseasePratishtha Chatterjee, Steve Pedrini, Erik Stoops, et al.
JAMA Network Open|December 3, 2025
Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive DeclineCalvin Trieu, Argonde C van Harten, Mardou S S A van Leeuwenstijn, et al.
Molecular Neurodegeneration|November 10, 2024
CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individualsMarta Del Campo, Carlos Quesada, Lisa Vermunt, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Journal of Alzheimer'S Disease : JAD|February 2, 2024
The Association of Alzheimer's Disease-Related Blood-Based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in KinshasaMegan Schwinne, Alvaro Alonso, Blaine R Roberts, et al.
Alzheimer'S Research & Therapy|December 20, 2024
Analytical and clinical performance of eight Simoa<sup>®</sup> and Lumipulse<sup>®</sup> assays for automated measurement of plasma p-tau181 and p-tau217Anna L Wojdała, Jeroen Vanbrabant, Sherif Bayoumy, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 7, 2024
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohortsGiovanni Bellomo, Sherif Bayoumy, Alfredo Megaro, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 21, 2021
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tauShorena Janelidze, Sebastian Palmqvist, Antoine Leuzy, et al.
Alzheimer'S Research & Therapy|December 5, 2021
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231Sherif Bayoumy, Inge M W Verberk, Ben den Dulk, et al.
Alzheimer'S Research & Therapy|July 1, 2026
The potential of key Alzheimer's plasma biomarkers to mimic tau PET MUBADA-based disease stagingInge M W Verberk, Lotte A de Koning, Emma M Coomans, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 13, 2023
Association of plasma biomarkers with cognitive function in persons with dementia and cognitively healthy in the Democratic Republic of CongoJean Ikanga, Saranya Sundaram Patel, Blaine R Roberts, et al.
Translational Psychiatry|January 12, 2021
Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's diseasePratishtha Chatterjee, Steve Pedrini, Erik Stoops, et al.
JAMA Network Open|December 3, 2025
Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive DeclineCalvin Trieu, Argonde C van Harten, Mardou S S A van Leeuwenstijn, et al.
Molecular Neurodegeneration|November 10, 2024
CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individualsMarta Del Campo, Carlos Quesada, Lisa Vermunt, et al.
Pageof 8